Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s patient-centric model of innovation leverages proven biology and technology to efficiently allocate research and development resources, while addressing strategic gaps related to access, delivery, quality of life, and efficacy in therapeutic areas of focus.

Viridian’s most advanced program, VRDN-001, is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody in development for thyroid eye disease (TED), a debilitating auto-immune disease that causes inflammation and fibrosis of the orbital tissues surrounding the eye, leading to proptosis, or bulging of the eyes, redness and swelling, diplopia (double vision), pain, and potential blindness. Historically, these patients have had poor treatment options limited to orbital surgeries, radiation, and steroids.

The company is based in Boulder, Colorado, and Waltham, Massachusetts.

Learn more about Viridian and our programs in our corporate presentation.